GlassScriptPhysician profile
Dennis Kim
NPI 1487766382
$5,903.59
in general payments reported to CMS, 2019-2025
38 companies · $473 in 2025
The $473 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $577 · 2021: $1,033 · 2022: $1,109 · 2023: $827 · 2024: $1,032 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $972.16 | 2019-2024 | |
| Glaxosmithkline, LLC. | $849.64 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $615.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $374.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $372.76 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $287.36 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $220.20 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.02 | 2019-2022 | |
| Daiichi Sankyo INC. | $194.91 | 2019-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $176.40 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $172.92 | 2020-2024 | Xarelto |
| Amgen INC. | $145.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Mylan Specialty L.P. | $135.64 | 2022-2024 | Yupelri |
| Silk Road Medical, INC. | $132.75 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Otsuka America Pharmaceutical, INC. | $129.00 | 2023-2025 | Rexulti, Nuedexta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $108.50 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $100.35 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $83.14 | 2023-2025 | |
| Eisai INC. | $64.90 | 2020 | |
| Astellas Pharma US INC | $64.39 | 2019 | |
| Merck Sharp & Dohme LLC | $50.72 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $47.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.39 | 2022 | |
| Dexcom, INC. | $45.00 | 2024-2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $42.99 | 2019 | |
| Acerus Pharmaceuticals Corporation | $29.83 | 2021 | |
| Boston Scientific Corporation | $26.89 | 2020 | |
| Almatica Pharma LLC | $24.86 | 2022 | |
| Lundbeck LLC | $24.53 | 2024 | Rexulti |
| Radius Health, INC. | $24.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.86 | 2021 | |
| Alfasigma USA, INC. | $19.87 | 2021 | |
| Sanofi Pasteur INC. | $19.44 | 2025 | |
| Sumitomo Pharma America, INC. | $16.12 | 2025 | Gemtesa |
| Antares Pharma, INC. | $15.01 | 2022 | |
| Circassia INC. | $14.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.36 | 2019 | |
| Ibsa Pharma INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.